Can you imagine that a combination of natural active ingredients, such as propolis, cranberry, aloe vera, green tea, chamomile and calendula, in contact with teeth and gums at night can act against bacterial plaque, and also improve gum sensitivity? The discovery comes from a Brazilian dentist, Dr Eder Gonzaga de Oliveira, who developed the Desplac tooth gel.
Unlike conventional toothpastes, which contain silica and are recommended for mechanical use during brushing, the gel was formulated for prolonged action, without causing burning or irritation to the oral mucosa.
The starting point was a recurring complaint from patients who used orthodontic aligners: waking up with bad breath and without the feeling of a clean mouth after hours of using the device overnight. According to the specialist, this occurs because the aligners retain part of the saliva next to the teeth during sleep, favoring the proliferation of bacteria, the increase in bad odor and the formation of dental biofilm. Over time, this process can trigger gum inflammation and increase the risk of developing periodontal disease.
“What we observed in clinical practice is that there was an important gap in oral care, especially during the night. By acting at this time, DesPlac not only resolves real discomfort, but expands the way we understand oral hygiene”, says Dr. Eder.
Studies carried out over two years by researchers linked to USP in Ribeirão Preto demonstrated that the combination of these active ingredients acts in a complementary way in the oral environment, helping to modulate bacterial activity, interfere with the organization of the biofilm and reduce gingival inflammatory processes. The formula is composed of approximately 77% natural ingredients, has a pH of 6.8 and is free of fluoride, parabens, triclosan, silicone, abrasives and detergents.
As research progressed, DesPlac now has two versions: one for daily brushing, aimed at controlling plaque and gum health, and another developed for users of aligners and intraoral devices, with prolonged action during the night.
Actor as ambassador
Actor Daniel Rocha says he accepted the invitation to be an ambassador after trying the product. According to him, the decision was influenced by a personal experience. “When they asked me to be an ambassador, I said: ‘Man, let me use the product’. I have very sensitive gums, I’ve been taking care of them for years, I do everything right, I use dental tape, and yet I’ve always had sensitivity”, he says.
After starting use, Daniel claims to have noticed an improvement in his condition. “I started using it and saw my gums improving. My father, who is a dentist, also observed this evolution”, he says. Interested in understanding the technology behind the product, he took scientific studies related to the development of the formula to his father.
The oral care category is experiencing a transformation driven by consumers who are more aware of their health. The focus, previously concentrated on freshness and whitening, makes room for solutions that deliver effectiveness, safety and continuous protection of the oral cavity. “We are building a category, a deeper movement, which involves education, clinical practice and behavior change”, says CEO Eduardo Zaborowski, who is the son of actress Viviane Pasmanter and businessman Gilberto Zaborowski.
SHORTS
Eurofarma reduces prices of weight loss pens
Eurofarma announced a reduction of up to 48% in the prices of Poviztra and Extensior weight loss pens, medicines based on original biological semaglutide sold in Brazil since last year. With the change, Poviztra now has a starting price of R$295 per box in dosages of 0.25 mg and 0.5 mg for participants in the EuroCuida support program. According to the pharmaceutical company, the estimated cost of the first three months of treatment will be R$899. The initiative seeks to expand patients’ access to weight control therapies in a market that has been registering strong growth in demand for medications in this class.
Genetics for the skin
Genera and O Boticário announced a partnership that integrates genetics and skin care. Customers of the Genera Premium package will have access to the Botik & Genera panel, which analyzes genetic variations associated with characteristics such as collagen production, elasticity, acne, oiliness, sun sensitivity and vitamin C metabolism. Based on this data, the platform cross-references DNA information with Botik line assets to offer personalized skincare recommendations. “We are expanding the use of genetics beyond self-knowledge in health and ancestry. The initiative creates a model of experience driven by science and data within skin care retail, a movement aligned with the global trend towards personalization and more informed purchasing decisions”, says Gustavo Mills, Business Manager at Genera.
Cellera Farma expands portfolio
Cellera Farma has just announced a strategic agreement with Sanofi to assume the exclusive promotion, marketing and distribution in Brazil of the medicines Puran®, a reference in the treatment of hypothyroidism, and Zinpass Eze®, indicated for controlling cholesterol. With the operation, the Brazilian pharmaceutical company begins to operate in the cardiometabolic segment and plans to achieve revenue of approximately R$1.32 billion in the coming months. “This partnership accelerates our growth strategy and strengthens our presence in therapeutic areas of great relevance to the Brazilian population”, says Omilton Visconde Jr., CEO of Cellera Farma.
Axé with Rogério Filhos do Sol
Axé is gaining more and more space in gyms and dance studios, driven by the search for activities that combine physical exercise, fun and well-being. In São Paulo, professor Rogério Filhos do Sol has brought together students of different ages in classes that mix vibrant choreography and the contagious energy of Bahian rhythms. Classes take place on Mondays and Wednesdays, at 11am, at Bodytech Iguatemi; on Mondays and Wednesdays, at 7pm, at the Eldorado unit; and at 9pm, at Estúdio Filhos do Sol, in Vila Prudente. On Tuesdays and Thursdays, classes are held at 6pm at Ultra Paulista and at 8pm at Bodytech Jardins.
Oncology leads Pfizer’s investments in innovation
Oncology is today one of Pfizer’s most strategic areas, concentrating around 40% of the company’s global investment in research and development. With 52 programs underway and more than 30 new molecular entities in development, the pharmaceutical company is betting on innovative therapies to expand treatment options against cancer. The goal is to launch eight new treatments by 2030 and double the number of patients benefiting from its oncology medications in the coming years. “We are at the forefront of a new era in cancer treatment, with a portfolio that brings together different mechanisms of action to attack the disease from multiple angles”, says Camilla Gaspari, oncology medical leader at Pfizer Brazil.
Robotic knee surgery
The first robotic-assisted orthopedic surgery with technology developed in China and adapted to the national market by Biomecanica. The procedure, knee surgery performed in a public hospital, combines international technology transfer and product implants in the country, expanding the perspectives of access to innovation in the SUS.
“The technology works as a support tool for the surgeon, who maintains total control over the procedure. The system assists in pre-operative planning and provides real-time information during surgery, contributing to greater precision in the positioning of implants and more predictability of results”, says Ana Carolina Pengo, CVO at Biomecanica.
